Hutchings, M., Zelenetz, A. D., Christensen, J. H., Hernandez, A. C., Assouline, S. E., Castillo, L. E. M., Kothari, S., Modi, D., Albendea, M. Ã. C., Cubillas, D., Garcia-Sancho, A. M., Diefenbach, C. S., Kuruvilla, J., Caimi, P. F., Patel, K., Landrette, S., Zhi, X., Zhang, Y., Meier, R., Matasar, M. (2026). Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps7103